Ryann Grochowski Jones was the data editor at ProPublica. Previously, she was a data reporter at ProPublica and at Investigative Newsource/KPBS in San Diego, California. She received her master’s degree from the University of Missouri School of Journalism, where she was a data librarian for Investigative Reporters and Editors/National Institute for Computer-Assisted Reporting. Ryann started her career as a municipal beat reporter for her hometown newspaper in Wilkes-Barre, Pennsylvania.
Where a hospital is located makes a big difference in how many of its doctors take payments from drug and medical device companies. See how your state compares and look up your hospital.
The more money doctors receive from drug and medical device companies, the more brand-name drugs they tend to prescribe, a new ProPublica analysis shows. Even a meal can make a difference.
We've updated our database of Medicare’s payments to individual doctors and other health professionals serving the 49 million seniors and disabled in its Part B program.
Pharmaceutical and medical device companies paid billions to doctors from late 2013 through 2014, new data shows. Search for your doctor in our interactive database.
New data on payments from drug and device companies to doctors show that many doctors received payments on 100 or more days last year. Some received payments on more days than they didn't.
Congress wouldn’t allow Medicare to pay for benzodiazepines such as Xanax and Ativan until 2013. Now, the medications are among the most prescribed in its drug program.
The ridesharing service published a report last week with Mothers Against Drunk Driving connecting the rise of Uber to a drop in drunk driving accidents. Except the connection isn't so clear.
Our comprehensive analysis of drug company spending on doctors in the last five months of 2013 shows the most-promoted products typically were not cures, breakthroughs or top sellers.
Beginning in 2014, the federal government mandated that pharmaceutical and medical device manufacturers publicly report payments made to doctors and teaching hospitals. The first report covered the last five months of 2013. Use this tool to search for a company, drug or device — and compare it to another.
Despite warnings about abuse, Medicare covered more prescriptions for potent controlled substances in 2012 than it did in 2011. The program's top prescribers often have faced disciplinary action or criminal charges related to their medical practices.
Thank you for your interest in republishing this story. You are are free to republish it so long as you do the following:
You have to credit ProPublica and any co-reporting partners. In the byline, we prefer “Author Name, Publication(s).” At the top of the text of your story, include a line that reads: “This story was originally published by ProPublica.” You must link the word “ProPublica” to the original URL of the story.
If you’re republishing online, you must link to the URL of this story on propublica.org, include all of the links from our story, including our newsletter sign up language and link, and use our PixelPing tag.
If you use canonical metadata, please use the ProPublica URL. For more information about canonical metadata, refer to this Google SEO link.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week,” and “Portland, Ore.” to “Portland” or “here.”)
You cannot republish our photographs or illustrations without specific permission. Please contact [email protected].
It’s okay to put our stories on pages with ads, but not ads specifically sold against our stories. You can’t state or imply that donations to your organization support ProPublica’s work.
You can’t sell our material separately or syndicate it. This includes publishing or syndicating our work on platforms or apps such as Apple News, Google News, etc.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually. (To inquire about syndication or licensing opportunities, contact [email protected].)
You can’t use our work to populate a website designed to improve rankings on search engines or solely to gain revenue from network-based advertisements.
We do not generally permit translation of our stories into another language.
Any website our stories appear on must include a prominent and effective way to contact you.
If you share republished stories on social media, we’d appreciate being tagged in your posts. We have official accounts for ProPublica on Twitter, Facebook and Instagram.
Copy and paste the following into your page to republish: